High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Christiane Pott et al.|Blood|2015Cited by 157
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Hervé Tilly, Cédric Rossi et al.|Blood Advances|2021Cited by 51
High <i>PDL1/PDL2</i> gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Fabrice Jardin, Pierre‐Julien Viailly et al.|Blood Advances|2023Cited by 17
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa CentersVincent Camus, Hervé Tilly, Alina Berriolo-Riedinger et al.|Blood|2020Cited by 3
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACEVincent Camus, Fabrice Jardin, Mathieu Viennot et al.|Blood Advances|2024Cited by 1